Stanford turns lymphoma driver BCL6 into a cancer kill switch

Stanford Medicine researchers built a two-part molecule, TCIP3, that links the lymphoma-driving protein BCL6 to P300/CBP and activates cell-death genes. In mice with aggressive B-cell lymphoma, tumors disappeared within 11 days of twice-daily treatment with no obvious toxicity. The study was published in Cell.

• TCIP3 links BCL6 to P300 and CBP, switching on cell-death genes
• Tumors in mice vanished within 11 days of twice-daily dosing
• TCIP3 killed lab-grown lymphoma cells at very low concentrations
• The approach may extend to autoimmune diseases such as rheumatoid arthritis